CPhI South East Asia’s (March 12-14, 2019) first visit to the fast-growing pharma economy of Thailand “could not come at a better moment”, the event’s organizers report. Thailand is experiencing a boom amongst pharma manufacturers and rising demand for contract services, with multinational corporations increasingly looking for local partners to expedite market access into the wider region. Over the next five years, the pharma industry in Thailand is anticipated to grow by CAGR of 7% and reach THB 275bn by 2026. Growth is being driven by healthcare and pharmaceutical reforms, designed to increase access to high-value medicines, which is sustaining imports from both the United States and Europe. Meanwhile, generic medicines demand both regionally and international is resulting in robust exports growth. Emphasizing the interest from international pharma markets, pre-registration figures for the CPhI event have “more than tripled ahead of what will be the 8th edition in this fast-emerging pharma hub”. The show floor itself has grown by over 50% year-on-year, the organizers report, “further highlighting the renewed confidence amongst exhibitors in South East Asia”. Beyond the exhibition, the CPhI South East Asia Conference brings together the main regional pharmaceutical associations and regulators to help accelerate integration and partnerships. The conference is an opportunity to hear the most cutting-edge insights, learn new trends and exchange ideas. Key sessions will explore the ‘ASEAN Regulatory Framework’ and ‘FDA Framework and the requirements for importing APIs to Thailand by the FDA and the Ministry of Public Health’. Another highlight is the Exhibitor Seminars, which feature in-depth sessions on new products and innovations, as well as informative content from heavyweight knowledge partners: Clarivate Analytics, IQVIA and Affygility. The business matchmaking service will also once again be available to attendees – serving as an online tool to arrange meetings before the event, ensuring attendees maximise their time onsite. https://www.cphi.com/sea/
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.